| Document |
Document Title |
|
WO/2022/002078A1 |
The present invention relates to the fields of pharmaceutical chemistry and pharmacotherapeutics, and in particular to a compound as represented by general formula I, a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable...
|
|
WO/2021/262311A1 |
The present disclosure is directed to a compound or compositions comprising the same for decreasing vascular permeability and the prevention or inhibition of metastasis in a cancer.
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/244244A1 |
Disclosed is an oxadiazole compound having a novel structure and as represented by general formula I: a compound of the general formula I has excellent bactericidal activity, and has a good prevention and control effect for plant bacteri...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/243001A1 |
Provided are compounds of Formula (I): (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
|
|
WO/2021/239568A1 |
The present invention relates to a process for the preparation of substituted 4-(N'-hydroxy- carbamimidoyl)benzoic acids, which can be obtained by nitrilase catalyzed hydration of substituted terephthalonitriles of formula (II) in an aqu...
|
|
WO/2021/215393A1 |
Provided is the compound, or a salt thereof, represented in formula (I). (In formula (1): Ar indicates a C6-10 aryl group, etc.; R1 indicates a cyano group, a thiocarbamoyl group, etc.; R2 indicates a hydrogen atom, etc.; R 3 indicates a...
|
|
WO/2021/209383A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to meth...
|
|
WO/2021/204666A1 |
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X and Y represent radicals such as hydrogen, alkyl and halogen. Z1 and Z2 represent radicals such as alkyl, cycloalkyl and ...
|
|
WO/2021/204669A1 |
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...
|
|
WO/2021/204667A1 |
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...
|
|
WO/2021/204665A1 |
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X, Y and Z represent radicals such as hydrogen, alkyl and halogen. Q represents a heterocyclic ring such as tetrazolyl.
|
|
WO/2021/197852A1 |
The presented invention relates to crystalline form, Form A of Ozanimod hydrochloride, processes for preparation thereof and pharmaceutical compositions comprising the Ozanimod hydrochloride Form A.
|
|
WO/2021/195413A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate rec...
|
|
WO/2021/195397A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate rec...
|
|
WO/2021/195396A1 |
Compounds are provided having the structure of Formula (I): (Formula (I)) or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1...
|
|
WO/2021/187486A1 |
The present invention relates to the compound represented in formula (1) or a pharmaceutically acceptable salt thereof (in the formula, Q1 represents a halogen, Q2 represents a hydrogen, etc., X, Y and Z represent a nitrogen atom or an o...
|
|
WO/2021/173930A1 |
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
|
|
WO/2021/160470A1 |
The present invention relates to a process for the preparation of aromatic carbonyl compounds of formula I, which can be obtained through reaction of compounds of formula II with molecular oxygen in the presence of a solvent and a cataly...
|
|
WO/2021/156175A1 |
The present invention relates to a process for the preparation of substituted 3-aryl-5- trifluoromethyl-1,2,4-oxadiazoles of formula (I), which can be obtained through reaction of amidoxime compounds of formula (II) with a haloacetic est...
|
|
WO/2021/156174A1 |
The present invention relates to a process for the preparation of substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles of formula I, which can be obtained through reaction of amidoxime compounds of formula II with a haloacetic ester in...
|
|
WO/2021/142186A1 |
Discloased is a pharmaceutical composition comprising: an active ingredient of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof: (I); and one or more excipient selected from the group consisting of a bin...
|
|
WO/2021/130492A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.
|
|
WO/2021/127301A1 |
4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarb...
|
|
WO/2021/110498A1 |
The present invention relates to a process for the preparation of substituted aromatic carboxamides of formula I, (formula I) which can be obtained through reaction of an aromatic carboxylic acid halide and an amine, whereas the process ...
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/102204A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2021/094505A1 |
The present invention relates to compounds Formula (I) wherein Q, R2, R3 and R4 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compounds and/or ...
|
|
WO/2021/092163A1 |
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
|
|
WO/2021/090282A1 |
The present invention discloses a compound of formula (I), wherein, R1, R2, R3, R4, A1 and Q are as defined in the detailed description and a process for preparing the compound of formula (I). The present invention also discloses a metho...
|
|
WO/2021/078174A1 |
Provided are a chiral sulfur oxide-containing aryl formamide compound and salt thereof, a preparation method therefor, a herbicidal composition, and an application. The structure of the compound is represented by formula I, wherein Z 1 a...
|
|
WO/2021/073643A1 |
The present application relates to the field of medicine, relates to drugs for treating non-alcoholic steatohepatitis, in particular, to linked cyclic compounds for treating non-alcoholic steatohepatitis, more in particular, to a compoun...
|
|
WO/2021/068950A1 |
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/043116A1 |
Disclosed are biphenyl compounds, a preparation method therefor, and the medical use thereof. The structure of the biphenyl compounds is as shown in formula (I) or formula (II). The biphenyl compounds of the present invention or a pharma...
|
|
WO/2021/041546A1 |
Compositions and methods for treating excising trinucleotide repeats, as well as for treating diseases and disorders associated with trinucleotide repeats are encompassed.
|
|
WO/2021/031788A1 |
Disclosed are an immune checkpoint inhibitor capable of blocking a PD-1/PD-L1 signaling pathway, a phenyl-substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt, racemate, optical isomer or solvent compound...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/013969A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/009306A1 |
The present invention relates to the process of preparation of compound of formula (I) or a salt thereof. Further it relates to the solid form of compound (I).
|
|
WO/2021/001825A1 |
The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides...
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/243415A2 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2020/242933A1 |
This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for improving memory, treating or preventing cancer, neu...
|
|
WO/2020/233618A1 |
Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition com...
|
|
WO/2020/234424A1 |
The present invention relates to new compounds which are benzo[c][1,2,5]oxadiazole derivatives, and the use thereof in the treatment of infectious diseases caused by Helicobacter pylori. Also, the present invention relates to a pharmaceu...
|
